Table 1.

Characteristics of the 20 study participants

Characteristic
Age, median (range) years	63 (40‐86)
Sex, no. (%)
Male	17 (85%)
Female	3 (15%)
Ethnicity, no. (%)
African	1 (5%)
Asian	1 (5%)
Māori	4 (20%)
NZ European	13 (65%)
Pacific peoples	1 (5%)
Years of education, median (range) a	16 (10‐20)
Disease duration, median (range) years	12 (2‐54)
Body mass index, median (range)	29 (26‐38)
Serum urate concentration, median (range), mmol/l	0.30 (0.20‐0.42)
Allopurinol dose, median (range), mg/day	300 (100‐600)
On antiinflammatory prophylaxis, no. (%)	0 (0%)
Gout flares in the last 12 months, no. (%)
0	18 (90%)
≥1	2 (10%)
Prior subcutaneous tophi, no. (%)	5 (25%)
Current subcutaneous tophi, no. (%) b	3 (15%)
Pain due to gout in the last month (0‐ to 10‐point scale), median (range)	0 (0‐5)
Patient global assessment of gout disease activity in the last week, (0‐ to 10‐point scale), median (range)	0 (0‐6)
Self‐perceived remission, no. (%) c	19 (95%)
Fulfilment of preliminary remission criteria at 12 months, no. (%) c	16 (80%)

Abbreviation: NZ, New Zealand.

^a Total including primary (up to 8 years), secondary (up to 5 years), and tertiary education (up to 7 years or more).

^b Presence of tophi was confirmed by a physician.

^c Assessed at a single point in time.